About Aerovate Therapeutics
Aerovate Therapeutics is a publicly listed company based in Boston (United States) founded in 2018 by Benjamin T Dake. Therapeutic solutions for pulmonary arterial hypertension are developed. Aerovate Therapeutics has raised $75.82 million across 1 funding round from investors including Atlas Venture, Sofinnova and Osage University Partners. The company has 31 employees. Aerovate Therapeutics offers products and services including AV-101. Its focus areas include Life Sciences, Pulmonology, Drugs and Pulmonary Arterial Hypertension. Its legal entity is Aerovate Therapeutics, Inc. Its competitors include Centessa Pharmaceuticals, Vivus and CoTherix; 2 of its 3 listed competitors have raised funding.
Company details
Aerovate Therapeutics was founded in 2018 and is based in Boston, United States. Focus is placed on the biotechnology sector, where inhaled therapies for rare cardiopulmonary diseases, including pulmonary arterial hypertension, are developed. Operations center on AV-101, an inhaled dry powder formulation of imatinib designed to target diseased lung tissues directly while minimizing systemic side effects. Clinical advancement of such treatments is pursued to address unmet needs in patient care.
- Headquarters Boston, United States
- Employees 31
- Founders Benjamin T Dake
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website aerovatetx.com
- Social LinkedIn X
- Legal Name Aerovate Therapeutics, Inc.
- Net Profit-$69.63 M (USD)8as on Dec 31, 2024
- EBITDA-$74.6 M (USD)8as on Dec 31, 2024
- Total Equity Funding$75.82M (USD)
in 1 rounds
- Latest Funding Round$75.82M (USD), Series A
Aug 2020
- InvestorsAtlas Venture
& 2 more
- Employee Count31
Products & Services of Aerovate Therapeutics
Aerovate Therapeutics offers a comprehensive portfolio of products and services, including AV-101.
Investigational inhaled formulation for treating rare cardiopulmonary diseases.
Funding Insights of Aerovate Therapeutics
Aerovate Therapeutics has successfully raised a total of $75.82M through 1 strategic funding round. The most recent funding activity was a Series A round of $75.82 million completed in August 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $75.82M
- Total Rounds 1
- Last Round Series A — $75.82M
- First Round $75.82M
(Aug 2020)
- Investors Count 3
All 1 funding rounds of Aerovate Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2020 | $75.82M | Series A | – | Sofinnova Investments |
3 investors in total: 3 institutional.
Investors in Aerovate Therapeutics
Aerovate Therapeutics has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Atlas Venture, Sofinnova and Osage University Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Biotech funding, drug development support, and investment in life sciences. | sofinnova.com | |||
Venture capital firm investing in life science and biotechnology sectors | 1980 | atlasventure.com | Cambridge, United States | |
Early- to growth-stage startups are targeted for venture capital investments. | oup.vc | Bala Cynwyd, United States |
Investor details for Aerovate Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Aerovate Therapeutics
13 people are tracked at Aerovate Therapeutics (6 in leadership, 4 in board & advisors, 3 in team); the tracked headcount is 31.
| Name | Role | Group |
|---|---|---|
Benjamin T Dake | Founder | Leadership |
Deep Jain | Director, Drug Safety & Pharmacovigilance | Leadership |
Tim Noyes | CEO | Leadership |
Jonathan Langley | Vice President Medical Affairs | Leadership |
Laetitia Baudet-Mpoutou | Director Of Diversity, Equity, Inclusion And Belonging | Leadership |
Hunter Gillies | Chief Medical Officer | Leadership |
David Grayzel | Director | Board & advisors |
Maha Katabi | Director | Board & advisors |
Josh Resnick | Director | Board & advisors |
Donald Santel | Director | Board & advisors |
Sanjeev Khindri | SVP, Clinical Development | Team |
Cheryl Lassen | SVP, Clinical Development | Team |
Stephen Yu | SVP, Quality | Team |
Complete people profiles for Aerovate Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Aerovate Therapeutics
3 dated milestones of Aerovate Therapeutics across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Aerovate Therapeutics is founded.
- Funding First funding round of $75.8M.
- IPO Lists on the stock exchange (IPO).
Competitors of Aerovate Therapeutics
Aerovate Therapeutics has 3 listed competitors in our database, 2 of them funded. They include Centessa Pharmaceuticals, Vivus and CoTherix.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| centessa.com | 2021 | Boston, United States | $250M | 83 | Medicines for sleep-wake, neurological, neurodegenerative, and psychiatric disorders are developed. | |
| vivus.com | 1991 | Mountain View, United States | 59 | Developer of therapeutic solutions for obesity and sexual health | ||
| cotherix.com | 2000 | San Francisco, United States | $55M | Inhaled therapeutics for cardiopulmonary diseases were developed and licensed. |
Detailed competitors of Aerovate Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Pulmonology
3 companies that operate in the same segment as Aerovate Therapeutics (Pulmonology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | 329 | ||
Portable oxygen concentrators are supplied for respiratory therapy needs. | 2001 | Goleta, California, United States | USD 51.65 M | USD 348.67 M | 766 | |
Robotic microsurgical systems for endoscopy are developed. | 2007 | Redwood City, California, United States | USD 733.62 M | 91 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Aerovate Therapeutics
Complete news archive for Aerovate Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aerovate Therapeutics
Aerovate Therapeutics was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Aerovate Therapeutics is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Aerovate Therapeutics is a funded company, having raised a total of $75.82M across 1 funding round to date. The company's 1st funding round was a Series A of $75.82M, raised on Aug 2020.
Aerovate Therapeutics has 31 employees.
Aerovate Therapeutics was founded in 2018 and is based in Boston, United States. Focus is placed on the biotechnology sector, where inhaled therapies for rare cardiopulmonary diseases, including pulmonary arterial hypertension, are developed. Operations center on AV-101, an inhaled dry powder formulation of imatinib designed to target diseased lung tissues directly while minimizing systemic side effects. Clinical advancement of such treatments is pursued to address unmet needs in patient care.
Aerovate Therapeutics's top competitors include Vivus, Centessa Pharmaceuticals and CoTherix.
Aerovate Therapeutics offers AV-101.
Aerovate Therapeutics has 3 investors. Key investors include Atlas Venture, Sofinnova, and Osage University Partners.
Aerovate Therapeutics operates through Aerovate Therapeutics, Inc..